New antibody combo aims to tackle Hard-to-Treat multiple myeloma
NCT ID NCT02332850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body tolerates the combination. Participants receive the drugs intravenously, and the study tracks side effects and initial signs of tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Isatuximab (a monoclonal antibody) combined with carfilzomib and dexamethasone
What this could lead to
If successful, this could lead to a more effective treatment option for people with multiple myeloma that has returned or not responded to prior therapies.
What could go wrong
This is an early-phase trial focused on safety and dosing, so it is not yet known if the combination works better than existing treatments. Side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States